SABSW (STOCKS)
SAB Biotherapeutics, Inc. Warrant
$0.026600
+0.000000 (+0.00%)
Prev close: $0.026600
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Samuel J. Reich
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- —
- Employees
- 63
- P/E (TTM)
- —
- P/B (TTM)
- —
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $62.23M |
| Operating Expenses | $48.95M |
| Research and Development | $34.35M |
| Other Operating Expenses | $14.60M |
| Operating Income/Loss | -$48.95M |
| Income/Loss From Continuing Operations After Tax | $13.27M |
| Income/Loss From Continuing Operations Before Tax | $13.27M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | $13.27M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $13.27M |
| Net Income/Loss Available To Common Stockholders, Basic | $4.26M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $18.02M |
| Preferred Stock Dividends And Other Adjustments | $9.01M |
| Undistributed Earnings/Loss Allocated To Participating Securities, Basic | $9.01M |
| Basic Earnings Per Share | $0.22 |
| Diluted Earnings Per Share | -$0.79 |
| Basic Average Shares | 19,311,798 |
| Diluted Average Shares | 61,340,193 |
| Assets | $172.81M |
| Current Assets | $101.05M |
| Noncurrent Assets | $71.76M |
| Fixed Assets | $13.31M |
| Other Non-current Assets | $58.45M |
| Liabilities | $21.32M |
| Current Liabilities | $10.68M |
| Accounts Payable | $3.15M |
| Wages | $5.04M |
| Other Current Liabilities | $2.50M |
| Noncurrent Liabilities | $10.63M |
| Equity | $151.49M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $151.49M |
| Liabilities And Equity | $172.81M |
| Net Cash Flow From Operating Activities | -$44.78M |
| Net Cash Flow From Operating Activities, Continuing | -$44.78M |
| Net Cash Flow From Investing Activities | -$121.71M |
| Net Cash Flow From Investing Activities, Continuing | -$121.71M |
| Net Cash Flow From Financing Activities | $168.30M |
| Net Cash Flow From Financing Activities, Continuing | $168.30M |
| Net Cash Flow | $1.82M |
| Net Cash Flow, Continuing | $1.82M |
| Comprehensive Income/Loss | $13.60M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $13.60M |
| Other Comprehensive Income/Loss | $13.60M |